The efficacy and safety of combined administration of intravenous and topical tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled trials

Huazhang Xiong, Yi Liu, Yi Zeng, Yuangang Wu and Bin Shen

Abstract

Background: The combined administration of intravenous (IV) and topical tranexamic acid (TXA) in primary total knee (TKA) remains controversial. The purpose of this meta-analysis was to assess the efficacy and safety of combined administration of IV and topical TXA in primary TKA.

Methods: PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Web of Science, Google Search Engine and China National Knowledge Infrastructure databases were searched for randomized controlled trials (RCTs) comparing the combined administration of IV and topical TXA following primary TKA. The primary outcomes were total blood loss, maximum hemoglobin drop, and deep venous thrombosis (DVT) and/or pulmonary embolism (PE). The second outcomes were drainage volume and transfusion requirements. Data were analyzed using RevMan 5.3.

Results: A total of 6 RCTs involving 701 patients were included in the meta-analysis. The combined group provided lower total blood loss (MD = −156.34 mL, 95% CI = 241.51 to −71.18; P = 0.0003), drainage volume (MD = −43.54 mL, 95% CI = 0.16 to 1.44; P = 0.19), maximum hemoglobin drop (MD = −0.56 g/dl, 95% CI = 0.01 to 7.91; P = 0.09) and PE (RR 0.33, 95% CI, 0.01 to 7.91; P = 0.49) than IV TXA alone. No significant difference were found in terms of transfusion requirements (RR 0.48, 95% CI, 0.16 to 1.44; P = 0.19), DVT (RR 1.01, 95% CI, 0.14 to 7.12; P = 0.99) and PE (RR 0.33, 95% CI, 0.01 to 7.91; P = 0.49) between the two group. Subgroup analyses shows that the combined group was less total blood loss in non-tourniquet (P = 0.0008), topical TXA dose > 1.5 g (P < 0.00001) and number of IV TXA ≥ 2 doses (P = 0.005) of TXA compared with the IV group alone.

Conclusions: The available evidence indicates combined group were associated with lower total blood loss, drainage volume, and maximum hemoglobin drop. A similar transfusion requirement was found in both groups. Subgroup analyses demonstrates that total blood loss was less in patients with non-tourniquet, topical TXA dose > 1.5 g and number of IV TXA ≥ 2 doses of TXA. There was no increase the rates of DVT and PE.

Keywords: Total knee arthroplasty, Tranexamic acid, Intravenous, Topical, Blood loss

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Total knee arthroplasty (TKA) and total hip arthroplasty (THA) is an effective orthopedic procedure for patients with severe knee and hip diseases [1–4]. However, significant blood loss may occur due to hyper-fibrinolysis induced by surgical trauma or tourniquet. Thus, it often leads to significant postoperative anemia and transfusion requirements [5, 6]. Postoperative anemia may be an important issue associated with adverse events, including increased mortality and morbidity and prolonged hospitalization due to transfusion-related needs.

Tranexamic acid (TXA) is a synthetic lysine analog, it can competitively inhibit the activation of plasminogen and plasmin binding protein [7, 8]. Several randomized controlled trials (RCTs) [9, 10] and meta-analysis studies [11, 12] have shown that intravenous (IV) [13, 14], topical (TA) [8] or oral [15] application of TXA can successfully reduce blood loss and transfusions in primary TKA without increasing the risk of thrombosis. Recently, an increasing number of studies have focused on the issue that when compared with only IV or TA TXA, whether combination application of IV and topical TXA has additional benefits in primary TKA [16, 17]. Compared with IV TXA, TA application has the advantage of being easy to administer, it leads to 70% lower systemic absorption and thus may be a safer alternative to giving it systemically. Additionally, topical application of TXA has the advantage of inducing partial microvascular hemostasis by stopping fibrin clot dissolution in the affected area [4, 8, 11, 18]. Once topically applied, TXA is rapidly absorbed and achieves the effect of hemostasis.

Several meta-analyses [19–21] were performed to evaluate the combination of IV and topical TXA in primary TKA. However, it may have some limitations and the conclusion might have the bias: First, as they included both TKA and THA in the analysis [19, 20], they did not account for the difference in the type of surgery. It cannot draw meaningful conclusions, and we believed that stricter criteria need to be applied to determine the benefits of combining TXA in a meta-analysis. Second, these studies were also affected by many other confounding factors [19–21], such as the application of tourniquet or non-tourniquet, and different topical TXA dose or the number of IV TXA. Thus, subgroup analysis based on the application of tourniquet or non-tourniquet, and topical TXA dose (≤1.5 g or > 1.5 g) or the number of IV TXA (single or ≥2 doses) were conducted, resulting in more accurate conclusions. Therefore, because of this bias factor, the efficacy of the combined IV and topical TXA in primary TKA has not been clearly concluded. Currently, there have been some well-designed studies [21–24] comparing the efficacy of combined administration of IV and topical TXA versus IV-TXA alone during TKA. Thus, the authors performed a meta-analysis to assess the highest evidence-based (level I) studies in order to investigate the effectiveness and safety of combined IV and TA application of TXA versus single IV TXA after primary TKA in regarding with (1) blood loss, including total blood loss and drainage volume; (2) transfusion requirements and maximum hemoglobin drop; and (3) thromboembolic complications, including deep venous thrombosis (DVT) and/or pulmonary embolism (PE). Additionally, subgroup analyses were also conducted to evaluate the benefits of the application of tourniquet or non-tourniquet, different topical (≤1.5 g or > 1.5 g) or the number of IV TXA (single or ≥2 doses) for total blood loss, maximum hemoglobin drop and transfusion requirements.

Methods
The method used for this meta-analysis is based on the recommended PRISMA checklist guidelines [25]. The study was registered in the Research Registration Unique Identifying Number (review registry 249; http://www.researchregistry.com).

Search strategy
We searched the following electronic databases: PubMed (1966 to December 2017), Embase (1974 to December 2017), Cochrane Central Register of Controlled Trials (December 2017) and Web of Science (1990 to December 2017). To identify additional potential studies, we also used the Google Search Engine (December 2017) and China National Knowledge Infrastructure (December 2017). We used the following keywords to search the database above: (total knee arthroplasty OR total knee replacement OR TKA OR TKR) AND (Tranexamic acid OR TXA OR TA). A search strategy with “PubMed” as an example in a manuscript: #1 Total Knee Arthroplasty; #2 Total Knee Replacement; #3 TKA; #4 TKR; #5 #1 OR #2 OR #3 OR #4; #6 Tranexamic Acid; #7 TXA; #8 TA; #9 #6 OR #7 OR #8; #10 #5 AND #9. There is no restriction on language and region.

Inclusion criteria
The inclusion criteria for these studies were performed as follows: (1) studies were RCTs that included combined IV and topical application of TXA, and IV application of TXA; (2) patients were performed primary unilateral TKA; and (3) The outcomes of each RCTs included at least one of the following: blood loss, drainage volume, transfusion requirements, maximum hemoglobin drop, DVT, and PE. The studies were excluded if: (1) there were no sufficient outcomes; (2) revision or simultaneous bilateral total knee arthroplasty. All titles and abstracts were independently reviewed by two reviewers (XXX, XXX) to identify potential studies. These eligible studies were then obtained for inclusion
based on the review of the full text. The differences were resolved by consensus after discussion, or a third reviewer was consulted if necessary.

Assessment of methodological quality
Two reviewers (XXX, XXX) assessed independently the methodological quality as described by the Cochrane Collaboration for Systematic Reviews [26]. The six items included random sequence generation, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and other risks. The overall methodological quality of each included study was characterized as low (low risk of bias), high (high risk of bias), and unclear (unclear risk of bias). Additionally, the two reviewers (XXX, XXX) used the modified Jadad scale to assess the risk of bias of the included studies [27]. Studies obtaining 4 or more points (up to 8 points) is considered to be of high quality, and the differences will be resolved by consensus after discussion, and if necessary, the third reviewer was consulted (XXX).

Outcome measures
The effectiveness and safety of combined IV and TA application of TXA versus single IV TXA after primary TKA in this meta-analysis were compared. The primary outcomes were total blood loss, maximum hemoglobin drop, and deep venous thrombosis (DVT) and/or pulmonary embolism (PE). The second outcomes were drainage volume and transfusion requirements. Furthermore, Subgroup analysis was also performed based on whether the use of tourniquet and drainage tube to compare the additional benefits for blood loss.

Data extraction
Two reviewers (XXX, XXX) independently extracted outcomes from the included studies. Their data includes authors, publication year, patients, age, and the intervention method of TXA, the method of DVT prophylaxis and screening, blood transfusion criterion. If the study reported the same patient during the different follow-up period, we chose a longer follow-up time to avoid duplication of data.

Data synthesis
Statistical analyses of the meta-analysis were performed using RevMan 5 software (Version 5.3, the Cochrane Collaboration, UK). For continuous data, the mean differences (MD) and 95% confidence interval (CI) were calculated, such as total blood loss, drainage volume, and maximum hemoglobin drop. For dichotomous data, the risk ratio (RR) and 95% confidence interval (CI) were calculated, such as transfusion requirements, DVT or PE. The chi-squared test and I2 statistic were used to assess statistical heterogeneity. If the chi-squared test > 0.1 or the I² < 50%, the fixed-effects model was chosen. Otherwise, a random-effects model was chosen. Publication bias was tested independently using funnel plots of total blood loss, drainage volume, maximum hemoglobin drop, transfusion requirements and DVT. If the funnel plot was symmetric, there was a low potential for publication bias, or vice-versa.

Results
Search results
The flow chart in Fig. 1 shows the process by screening the potential studies. A total of 1689 studies were screened through the initial search, 1410 were excluded on the basis of their titles and abstracts, and then leaving 279 were read for full-text. After scanning full-text, 273 were also excluded since it did not meet inclusion criteria. Thus, 6 RCTs had been published between 2014 and 2017 used in the meta-analysis [16, 17, 22–24, 28]. These studies included 351 patients in combined administration of IV and topical TXA group (combined group) and 350 patients in IV TXA group (IV TXA group). Sample size in included trials ranged from 25 to 95. Of all 6 studies, 5 studies were published in the English language [16, 17, 22–24], 1 study was published in the Chinese language [28]. Randomization was conducted in all 6 studies [16, 17, 22–24, 28]. All but 1 study [28] reported randomization method, of which 4 studies [17, 22–24] were reported using a computer-generated randomization, and in 1 [16] study reported the use of sealed envelope technique. There were 4 studies [16, 17, 22, 24] performed a clear blinding. All but two studies [17, 22] performed drainage, and the tourniquet was applied in four studies [16, 17, 23, 24]. All patients in the included studies received DVT prophylaxis of physical and chemical methods, including intermittent pneumatic compression, low-molecular-weight heparin, aspirin or rivaroxaban. Table 1 summarizes the baseline characteristics of included studies.

Table 2 summarizes the methodological quality and the risk of bias of the included studies. All 6 trials were relatively well designed, and the modified Jadad scores showed that the quality of the 6 trials was high, of which there were 2 at least 4 points, there were 3 up to 7 points. The meta-analysis used independently funnel plots of total blood loss, drainage volume, maximum hemoglobin drop, transfusion requirements and DVT to assess publication bias; the plots were generally symmetrical and shown a lower publication bias (Fig. 2 A, B, C, D, E).

Meta-analysis of blood loss
A total of five studies [16, 17, 22–24] report relevant data regarding total blood loss (326 and 325 patients in the combined group and IV group, respectively). The outcome of meta-analysis indicates that total blood loss
found in the combined group significantly reduced blood loss by a mean of 156.34 mL compared with the IV group (95% CI, −241.51 to −71.18; \( P = 0.0003 \)) (Fig. 3). A random-effects model was used since there was significant heterogeneity among the studies (\( P = 0.002, I^2 = 77\% \)).

Subgroup analysis was performed base on the use of tourniquet or non-tourniquet, different topical (\( \leq 1.5 \) g or \( > 1.5 \) g) or number of IV TXA (single or \( \geq 2 \) doses) of TXA. The outcome revealed that there was the significant difference between the two groups in terms of tourniquet or non-tourniquet, topical TXA dose or the number of IV TXA (Table 3).

### 3.3 Meta-analysis of drainage volume

A total of three studies [16, 24, 28] reported relevant data regarding drainage volume (167 and 167 patients in the combined group and IV group, respectively). The outcome of meta-analysis indicates that drainage volume found in the combined group significantly reduced drainage volume by a mean of 43.54 mL compared with the IV group (95% CI, −67.59 to −19.48; \( P = 0.0004 \)) (Fig. 4). A fixed model was used since there was no significant heterogeneity among the studies (\( P = 0.34, I^2 = 7\% \)).

### Meta-analysis of maximum hemoglobin drop

A total of four studies [16, 17, 23, 24] reported relevant data regarding maximum hemoglobin drop (296 and 295 patients in the combined group and IV group, respectively). The outcome of meta-analysis indicates that maximum hemoglobin drop found in the combined group significantly reduced maximum hemoglobin drop by a mean of 0.56 g/dl compared with the IV group (95% CI, −0.93 to −0.19; \( P = 0.003 \)) (Fig. 5). A random-effects model was used since there was significant heterogeneity among the studies (\( P < 0.00001, I^2 = 90\% \)). Similar results were received in subgroup analysis based on the application of tourniquet or non-tourniquet, topical TXA dose or the number of IV TXA (Table 4).
| Author   | Diagnose | No. Of patients | Interventions | Drainage | Tourniquet | Transfusion criteria | DVT prophylaxis | DVT screen |
|----------|----------|----------------|---------------|----------|------------|---------------------|-----------------|------------|
| Huang [16] | OA       | VI: 92         | VI: 64.7      | Yes      | Yes        | 70 g/L ≤ Hb ≤ 90 g/L with anemia; Hb ≤ 70 g/L | LMWH Rivaroxaban | Ultrasound |
|          |          |                |               | Combined: 92 | Combined: 65.4 |                      |                 |            |
|          |          |                |               | Combined: 1.5 g used intravenously before inflation + 1.5 g used topically |       |                      |                 |            |
| Jain [17] | OA       | VI: 60         | VI: 70.0      | No       | No         | 7.0 g/dL ≤ Hb ≤ 8.0 g/dL with symptomatic anemia or Hb ≤ 70 g/dL | Aspirin         | Clinical+ ultrasound |
|          |          |                |               | Combined: 59 | Combined: 68.27 |                      |                 |            |
|          |          |                |               | Combined: Same IV dose + 2 g used before closure of arthroscopy |       |                      |                 |            |
| Nielsen [22] | NS      | VI: 30         | VI: 63.2      | No       | No         | Hb < 7.5 g/dL or < 10 g/dL with heart disease or Hb reduced > 25% | Rivaroxaban     | Clinical |
|          |          |                |               | Combined: 30 | Combined: 65.5 |                      |                 |            |
|          |          |                |               | Combined: Same IV dose + 3 g used after closure of the capsule |       |                      |                 |            |
| Lee [23] | OA       | VI: 93         | VI: 73.4      | Yes      | Yes        | 7.0 g/dL ≤ Hb ≤ 8.0 g/dL with symptomatic anemia or Hb ≤ 70 g/dL | Rivaroxaban, Aspirin | Clinical +CT |
|          |          |                |               | Combined: 95 | Combined: 72.1 |                      |                 |            |
|          |          |                |               | Combined: 10 mg/kg 30 min before deflation, same dose repeated 3 h later + 2 g injected. |       |                      |                 |            |
| Song [24] | OA       | VI: 50         | VI: 69.2      | Yes      | Yes        | Hb < 8 g/% | LMWH              | Ultrasound + CT |
|          |          |                |               | Combined: 50 | Combined: 70.8 |                      |                 |            |
|          |          |                |               | Combined: Same IV dose + 1.5 g used topically after wound closure |       |                      |                 |            |
| Liu [19]  | OA       | VI: 25         | VI: NS        | Yes      | Yes        | Hb ≤ 8 g/dL | Rivaroxaban  | Ultrasound |
|          |          |                |               | Combined: 25 | Combined: NS |                      |                 |            |
|          |          |                |               | Combined: same IV dose + 1 g 10 min before inflation |       |                      |                 |            |

Abbreviation: OA osteoarthritis, VI intravenous, NS not stated, DVT deep venous thrombosis, Hb hemoglobin, LMWH low-molecular weight heparin, CT computed tomographic
Meta-analysis of transfusion requirements
A total of five studies [16, 17, 22–24] reported relevant data regarding transfusion requirements (326 and 325 patients in the combined group and IV group, respectively). The outcome of meta-analysis indicates that transfusion requirements found 4 of 326 patients in the combined group, compared to 9 of 325 patients in the IV group. The risk ratio (RR) shown there was no significant difference between the two group in the incidence of transfusion requirement (RR = 0.48, 95% CI, 0.16 to 1.44; $P = 0.19$) (Fig. 6). A Fixed-effects model was used since there was no significant heterogeneity among the studies ($P = 0.69$, $I^2 = 0\%$). Similar results were received from subgroup analysis based on the application of the tourniquet or non-tourniquet, topical dose and number of IV TXA (Table 4).

Meta-analysis of DVT and PE
A total of six studies [16, 17, 22–24, 28] reported relevant data regarding DVT (351 and 350 patients in the

---

### Table 2 Quality assessment and modified Jadad score of included 6 randomized controlled trials

| Studies (years) | Random sequence generation | Allocation concealment | Blinding | Incomplete outcome data | Selective reporting | Other bias | Modified Jadad score |
|-----------------|----------------------------|------------------------|----------|------------------------|---------------------|-----------|----------------------|
| Huang (2014) [16] | Low | Low | Low | Low | Low | Low | Low | 8 |
| Liu (2015) [19] | Unclear | Unclear | Unclear | Low | Low | Low | Low | 4 |
| Jain (2016) [17] | Low | Low | Low | Low | Low | Low | Low | 7 |
| Nielsen (2016) [22] | Low | Low | Low | Low | Low | Low | Low | 8 |
| Lee (2017) [23] | Low | Low | Unclear | Low | Low | Low | Low | 6 |
| Song (2017) [24] | Low | Low | Low | Low | Low | Low | Low | 7 |

Abbreviation: Low:low risk of bias; Unclear: unclear risk of bias; High: high risk of bias

---

**Fig. 2** Funnel plot of total blood loss (a), drainage volume (b), maximum hemoglobin drop (c), transfusion requirements (d), and DVT (e)
combined group and IV group, respectively). There was 1 in each of the two groups. Of which, 1 of 92 patients [16] who received combination intravenous and topical TXA developed DVT, and 1 of 60 patients [17] who re-
ceived only intravenous TXA developed DVT (RR 1.01, 95% CI, 0.14 to 7.12; P = 0.99) (Fig. 7). All but 1 study [23] reported 1 PE found in the IVTXA (RR 0.33, 95% CI, 0.01 to 7.91; P = 0.49). Thus, no significant dif-
ferences were found in the two groups in terms of the incidence of DVT and PE. A fixed-effects model was used, since there was no significant heterogeneity among the studies (P = 0.34, I² = 0%).

Discussion

Tranexamic acid, an analog of the amino acid lysine, suc-
cessfully reduces perioperative blood loss and transfusion
requirements in primary TKA [5, 6, 29, 30]. TXA can be
applied during the perioperative period either intra-
venously [13, 31], topically [8, 32], and orally [15, 33]. Re-
cently, an increasing number of studies have focused on
the issue that when compared with only intravenous or
topical TXA, whether combination application of IV
and topical TXA has additional benefits in primary
TKA [16, 17, 22]. Thus, we performed the meta-
analysis to assess the efficacy and safety of com-
bined application versus intravenous application of
TXA in TKA.

The main finding of this meta-analysis is that the
combined application intravenous and topical of TXA
can significantly reduce postoperative total blood loss,
maximum hemoglobin drop compared to the application of intravenous TXA alone. Subgroup analyses showed that total blood loss was less in patients with non-tourniquet, topical TXA
dose > 1.5 g and IV TXA ≥ 2 doses. No significant dif-
fferences were found in the incidence of DVT and PE
between the two groups.

The administration of IV TXA in TKA has been
well established in a lot of literature. Akgül et al. [34]
reported 20 mg/kg IV-TXA given before the skin inci-
sion in the primary TKA could decrease the total
blood loss from 1166.42 mL to 634.03 mL and reduce
the drainage volume from 640.74 mL to 311.11 mL.
Pitta et al. [35] performed another retrospective study
involving 610 patients during 4 years, they reported
the administered IV of TXA resulted in a significant
decrease by 9.4% in blood loss compared to the
control group in TKA, and no significantly different was
found in the incidence of DVT. Compared with the
safety concerns with intravenous administration, top-
ical TXA has been a growing interest to prevent
bleeding. As previously reported, it was considered
to less of 70% systemic absorption and thus may be
a systemic alternative. Ishida et al. [36] conducted a
randomized controlled trial that injected 2000 mg/
20 mL topical TXA compared with a placebo group
in TKA, the results revealed that postoperative
decreasing in Hb level and knee joint swelling was sig-
nificantly reduced in the TXA group compared to
the control group. Recently, a new strategy of
combined administration of TXA was explored con-
sidering the advantages of both methods. A random-
ized, double-blind, placebo-controlled trial [22] of
60 patients comparing patients who received combined
IV and topical TXA or IV TXA in primary TKA
found that combined administration results in signifi-
cantly lower total blood loss and postoperative Hb
level, while the incidence of DVT was similar be-
tween the two groups. Lee et al. [23] have also found
the similar results that while there were no patients
in any study group received an allogeneic transfusion,
the combined group had lower total blood loss than
the IV-only group.

The current meta-analysis shows that combined group
could effectively reduce postoperative total blood loss by
about 156.34 mL compared with IV TXA alone. Simi-
larly, subgroup analysis suggested that there is also the
significant difference between the two group in terms of
the use of tourniquet or non-tourniquet, topical (≤1.5 g
or > 1.5 g) and the number of IV TXA (single or ≥ 2
doses). Furthermore, the meta-analysis indicates that
drainage volume found in the combined group signifi-
cantly reduced drainage volume by a mean of 43.54 mL
compared with the IV group. Thus, the combined

![Fig. 3 Forest plot analysis of total blood loss](image-url)
administration of TXA could be a reasonable alternative to IV TXA alone for decreasing blood loss and drainage volume in primary TKA.

In our meta-analysis, the rate of transfusion requirements was slightly less for the combined group than for the IV TXA group, but the difference was not statistically significant (RR 0.48, P = 0.19). Subgroup analyses showed similar results for the tourniquet or non-tourniquet and different topical or the number of IV TXA. Huang et al. [16] performed one RCT, 1.5 g topical TXA administered combined with 1.5 g IV-TXA, and there was no statistically significant difference regarding transfusion requirements between the two groups. Another RCT

### Table 3 Results of meta-analysis and subgroup analyses of the included studies

| Results (Combined vs. IV groups) | No. of studies / knee | P     | Effect Size | 95% CI | Heterogeneity p( I²) | Model |
|----------------------------------|----------------------|-------|-------------|--------|----------------------|-------|
|                                  |                      |       | MD/RR       |        |                      |       |
| 1. Total blood loss              |                      |       |             |        |                      |       |
| All studies                      | 5/651                | 0.0003| −156.34     | 241.51 to −71.18 | 0.002 (77%) | Random |
| Tourniquet or Non-tourniquet     |                      |       |             |        |                      |       |
| Tourniquet                       | 3/471                | 0.05  | −108.68     | −217.44 to 0.08 | 0.005 (81%) | Random |
| Non-tourniquet                   | 2/179                | 0.0008| −251.30     | −398.40 to −104.19 | 0.17 (47%) | Fixed |
| Topical TXA dose                 |                      |       |             |        |                      |       |
| ≤ 1.5 g                          | 2/284                | 0.10  | −54.93      | −119.43 to 9.57  | 0.33 (0%) | Fixed |
| > 1.5 g                          | 3/367                | < 0.00001 | −209.39 | −255.95 to −162.83 | 0.36 (1%) | Fixed |
| Number of IV TXA                 |                      |       |             |        |                      |       |
| Single dose                      | 2/244                | 0.13  | −210.91     | −485.30 to 63.47 | 0.03 (80%) | Random |
| ≥ 2 doses                        | 3/407                | 0.005 | −147.43     | −251.16 to −43.69 | 0.002 (84%) | Random |
| 2. Maximum hemoglobin drop       |                      |       |             |        |                      |       |
| All studies                      | 4/591                | 0.003 | −0.56       | −0.93 to −0.19  | < 0.00001 (90%) | Random |
| Tourniquet or Non-tourniquet     |                      |       |             |        |                      |       |
| Tourniquet                       | 3/472                | 0.05  | −0.52       | −1.04 to 0.00   | < 0.00001 (92%) | Random |
| Non-tourniquet                   | 1/119                | < 0.00001 | −0.68  | −0.88 to −0.48   | –      | –      |
| Topical TXA dose                 |                      |       |             |        |                      |       |
| ≤ 1.5 g                          | 2/284                | 0.006 | −0.21       | −0.35 to −0.06  | 0.17 (47%) | Fixed |
| > 1.5 g                          | 2/307                | < 0.00001 | −0.78  | −0.99 to −0.56   | 0.17 (47%) | Fixed |
| Number of IV TXA                 |                      |       |             |        |                      |       |
| Single dose                      | 1/184                | 0.03  | −0.17       | −0.33 to −0.01  | –      | –      |
| ≥ 2 doses                        | 3/407                | < 0.00001 | −0.73  | −0.93 to −0.54   | 0.21 (36%) | Fixed |
| 3. Transfusion requirements      |                      |       |             |        |                      |       |
| All studies                      | 5/651                | 0.19  | 0.48        | 0.16 to 1.44   | 0.69 (0%) | Fixed |
| Tourniquet or Non-tourniquet     |                      |       |             |        |                      |       |
| Tourniquet                       | 3/472                | 0.70  | 0.75        | 0.17 to 3.26   | –      | –      |
| Non-tourniquet                   | 2/179                | 0.28  | 0.05        | 0.05 to 1.64   | 0.89 (0%) | Fixed |
| Topical TXA dose                 |                      |       |             |        |                      |       |
| ≤ 1.5 g                          | 3/344                | 0.50  | 0.64        | 0.17 to 2.37   | 0.65 (0%) | Fixed |
| > 1.5 g                          | 2/307                | 0.21  | 0.25        | 0.03 to 2.21   | –      | –      |
| Number of IV TXA                 |                      |       |             |        |                      |       |
| Single dose                      | 2/244                | 0.50  | 0.64        | 0.17 to 2.37   | 0.65 (0%) | Fixed |
| ≥ 2 doses                        | 3/407                | 0.21  | 0.25        | 0.03 to 2.21   | –      | –      |
| 4. Drainage volume               |                      |       |             |        |                      |       |
| All studies                      | 3/334                | 0.0004| −43.54      | −67.59 to −19.48 | 0.34 (7%) | Fixed |
| 5. DVT                           | 6/701                | 0.99  | 101         | 0.14 to 7.12   | 0.34 (0%) | Fixed |

Abbreviation: RR, risk ratio; MDs, mean differences; IV, Intravenous; DVT, deep venous thrombosis
Fig. 4 Forest plot analysis of drainage volume

Fig. 5 Forest plot analysis of maximum hemoglobin drop

Fig. 6 Forest plot analysis of transfusion requirements

Fig. 7 Forest plot analysis of DVT
[23], 119 patients were randomized into combined group and IV group alone, the combined group provided better results than IV alone in total blood loss (590.69 ± 191.1 mL vs. 385.68 ± 182.5 mL, \( P < 0.001 \)), but no difference in blood transfusion rate (6.6% vs. 1.6%, \( P = 0.364 \)). The result of our meta-analysis evaluating transfusion rates was consistent with these studies.

Thromboembolic prophylaxis methods were performed in all of the studies and as follow: low-molecular-weight heparin, aspirin, and enoxaparin. As Anderson et al. [37] reported in “N Engl J Med”, they found that among patients who received 5 days of rivaroxaban prophylaxis following TKA/THA, extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of DVT. Additionally, all thromboembolic events were detected by clinical symptomatic, routine Doppler ultrasound, or CT angiography. Finally, there was 1 in each of the two groups. The total rate of DVT was 0.03%. There was no difference in both two group (\( P = 0.99 \)). 1 PE was found in the IV TXA group. Our findings are consistent with those of RCT [17, 23] or meta-analysis [38, 39] which found that no previous studies have reported increased rates of symptomatic DVT or PE with the combined administration of TXA in TKA.

The current study had the following strengths. First, all of the included studies have been well-designed and satisfied the defined eligibility criteria comparing the efficacy of combined TXA versus intravenous administration of TXA during TKA. Second, subgroup analysis was performed based on the use of the tourniquet or non-tourniquet and different topical or the number of IV TXA. The results showed that combined administration of TXA in TKA can effectively reduce total blood loss and maximum hemoglobin drop compared with IV TXA alone. Third, this study independently used funnel plots to assess publication bias, the plots were generally symmetrical and shown a lower publication bias. However, the meta-analysis also has limitations. First, the reported blood loss methods are not consistent, which may lead to deviations in the clinical outcome of blood loss. In addition, the method for estimating displacement is not detailed, so it cannot exclude the result deviation caused by human factors measurement. Second, the number of RCTs included was limited. Thus, more carefully and scientifically designed RCTs are needed in the future to further confirm and compare the different results. Third, due to the limited sample size of the study, our meta-analysis failed to extract adequate data pertaining to some items from these studies, such as function outcomes, patient satisfaction, and other complications, etc. Last, there was substantial heterogeneity in the meta-analysis of several outcomes, including total blood loss and drainage volume. However, taking into account the effects of the tourniquet and different topical TXA dose (≤1.5 g or > 1.5 g) or number of IV TXA (single or ≥2 doses), thus subgroup analysis was performed to decrease heterogeneity.

Conclusions
This meta-analysis of currently available evidence indicates that combined administration of intravenous and topical TXA in primary TKA can significantly reduce total blood loss, drainage volume and maximum hemoglobin drop compared with IV TXA alone. The main finding, however, is that there is no significant difference in transfusion rates because this is the most clinically relevant point in this meta-analysis.

Abbreviations
CI: Confidence interval; DVT: DVT; IV: Intravenous; MD: Mean differences; PE: Pulmonary embolism; RCT: Randomized controlled trials; RR: Risk ratio; SD: Standard deviation; TA: Tranexamic acid; TKA: Total knee arthroplasty; TKR: Total knee replacement; TXA: Tranexamic acid

Availability of data and materials
All data and materials are contained within the manuscript.

Authors’ contributions
Bin Shen conceived, designed and coordinated the experiments and drafted the manuscript. Huazhang Xiong and Yi Zeng contributed to data acquisition. Yi Zeng and Yuangang Wu analysed and interpreted the data. Huazhang Xiong and Bin Shen revised the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Ethical approval is not necessary because it is a comment on previously published articles and does not involve the handling of any personal patient data.

Consent for publication
All authors agree to publish.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province 610041, People’s Republic of China. 2Department of Orthopedic Surgery, The First Affiliated Hospital of Zunyi Medical College, Zunyi 563003, Guizhou Province, China.

Received: 23 February 2018 Accepted: 10 July 2018
Published online: 07 September 2018

References
1. Zorán JA Jr, Axe MJ, Snyder-Mackler L. Clinical predictors of elective total joint replacement in persons with end-stage knee osteoarthritis. BMC Musculoskelet Disord. 2010;11:86.
2. Levine BR, Haughom B, Strong B, Helfman M, Frank RM. Blood management strategies for total knee arthroplasty. J Am Acad Orthop Surg. 2014;22:361–71.
3. Edelstein AI, Kwasy MJ, Suleman B, Khakhkhar RH, Moore MA, Beal MD, et al. Can the American College of Surgeons risk calculator predict 30-day complications after knee and hip arthroplasty? J Arthroplast. 2015;30:5–10.
4. Wong J, Abirshami A, Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, et al. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010;92:2503–2513.
5. Chen JY, Chin PL, Moo HI, Pang HH, Tay DK, Chia SL, et al. Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: a double-blinded randomised controlled noninferiority trial. Knee. 2016;23:152–6.

6. Wu Y, Yang T, Zeng Y, Li C, Shen B, Pei F. Clamping drainage is unnecessary after minimally invasive total knee arthroplasty in patients with tranexamic acid-a randomized, controlled trial. Medicine. 2017;96:e5094.

7. Xie J, Ma J, Kang P, Zhou Z, Shen B, Yang J, et al. Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study with consecutive cases. Thromb Res. 2015;136:234–8.

8. May JH, Rieser GR, Williams CG, Markert RJ, Raoof NT. Tranexamic acid to reduce blood loss after bilateral total knee arthroplasty: a double-blind, randomized, controlled, noninferiority clinical trial. J Bone Joint Surg Am. 2014;96:1937–44.

9. Patel JN, Spanjer JM, Smith LS, Huang J, Yakkanti MR, Malkani AL. Comparison of intravenous versus topical tranexamic acid in total knee arthroplasty: a prospective randomized study. J Arthroplast. 2014;29:1528–31.

10. Alshyra S, Sarda P, Suikeli M, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg. 2011;93:577–85.

11. Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee. 2014;21:97–83.

12. Wei Z, Li M. The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2270 cases. Transfusion medicine (Oxford, England). 2015;25:151–62.

13. Charoecholvanich K, Siriwattanasakul P. Tranexamic acid reduces blood loss and blood transfusion after TKA: a prospective randomized controlled trial. Clin Orthop Relat Res. 2011;469:2874–80.

14. Tzatzakis TK, Drosos GI, Kotsios SE, Ververidis AN, Vogiatzaki TD, Kazlos KI. Intravenous vs topical tranexamic acid in Total Knee arthroplasty without tourniquet application: a randomized controlled study. J Arthroplast. 2016;31:2465–70.

15. Lee OJ, Ching WY, Wong YC. Blood sparing efficacy of oral tranexamic acid in primary Total knee arthroplasty: a randomized controlled trial. Knee surgery & related research. 2017;29:57–62.

16. Huang Z, Ma J, Shen B, Pei F. Combination of intravenous and topical application of tranexamic acid in primary total knee arthroplasty: a prospective randomized controlled trial. J Arthroplast. 2014;29:2342–6.

17. Jain NP, Nishane PP, Shah NA. Combined Administration of Systemic and Topical Tranexamic Acid for Total knee arthroplasty can it be a better regimen and yet safe? A randomized controlled trial. J Arthroplast. 2016;31:542–7.

18. Seo JG, Moon YW, Park SH, Kim SM, Ko KR. The comparative efficacies of intra-articular and IV tranexamic acid for reducing blood loss during total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2013;21(8):1869–74.

19. Shang J, Wang H, Zheng B, Rui M, Wang Y. Combined intravenous and topical tranexamic acid versus intravenous use alone in primary total knee and hip arthroplasty: a meta-analysis of randomized controlled trials. Int J Surg. 2016;36:324–9.

20. Li JF, Li H, Zhao H, Wang J, Liu S, Song Y, Wu HF. Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomized controlled trials. J Orthop Surg Res. 2017;12:1122.

21. Wang Z, Shen X. The efficacy of combined intra-articular and intravenous tranexamic acid for blood loss in primary total knee arthroplasty: a meta-analysis. Medicine. 2017;96(42).

22. Nielsen CS, Jans O, Orndes T, Foss NB, Troelsen A, Husted H. Combined intra-articular and intravenous tranexamic acid reduces Blood loss in Total knee arthroplasty: a randomized, double-blind, placebo-controlled trial. J Bone Joint Surg Am. 2016;98:835–41.

23. Lee SY, Chong S, Balasubramaniam D, Na YG, Kim TK. What is the Ideal Route of Administration of Tranexamic Acid in TKA? A Randomized Controlled Trial. Clin Orthop Relat Res. 2017;475:1987-96.

24. Song EK, Seon JK, Parkah J, Seol YJ, Park YJ, Jin C. Combined administration of IV and topical tranexamic acid is not superior to either individually in primary navigated TKA. J Arthroplast. 2017;32:37–42.

25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Medicine: a peer-reviewed, independent, open-access journal. 2009;3:123–30.